Informa
TIDES Asia: Oligonucleotide & Peptide Therapeutics
2025年2月26-28日
日本京都, Westin Miyako Kyoto

主會議 第3天

主會議 第3天

8:00am - 8:10am10分鐘
Registration and Coffee
報到・咖啡時光
    Plenary Session
    主題講演單元
    8:10am - 8:15am5分鐘
    Plenary Sessions
    主題講演單元
    Chairperson’s Remarks: Plenary Day 3
    主席致辭：主題講演（第3天）
      8:15am - 8:45am30分鐘
      Plenary Sessions
      主題講演單元
      Lipid Nanoparticles for mRNA Vaccine Delivery
      用於 mRNA 疫苗遞送的脂質納米顆粒
      • Mate Vadovics, PhD - Postdoctoral Fellow, Norbert Pardi Lab, University of Pennsylvania
      8:45am - 9:15am30分鐘
      Plenary Sessions
      主題講演單元
      LEAD (Ligand- and Enhancer-Assisted Delivery) Enables Efficient siRNA Delivery to Immune Cells by Targeting a Cell Type-Specific Receptors
      LEAD（配體和增強劑輔助遞送）透過靶向細胞類型特異性受體，實現將 siRNA 高效遞送至免疫細胞
      • Weimin Wang, PhD - Founder & CEO, Sanegene Bio
      9:15am - 9:45am30分鐘
      Plenary Sessions
      主題講演單元
      Phase 1 Clinical Testing of a First-in-Class ASO Therapeutic against Metastatic Cancer
      治療轉移性癌症的 first-in-class ASO 療法的 I 期臨床試驗
      • Zdravka Medarova, PhD - Co-Founder and Chief Scientific Officer, TransCode Therapeutics
      9:45am - 10:15am30分鐘
      Plenary Sessions
      主題講演單元
      Targeting lncRNA TUG1 for Treatment of Patients with GBM by Using a Novel DDS System for ASO
      使用新型 ASO DDS 系統標靶 lncRNA TUG1 治療 GBM 患者
      • Shiro Akinaga, PhD - President and CEO, NANO MRNA, Co., Ltd.
      10:15am - 10:55am40分鐘
      Networking Refreshment Break with Poster and Exhibit Viewing
      上午互動交流休息時間，觀賞海報和展覽
        Concurrent Conference Tracks
        同時進行的各個分會
        10:55am - 11:00am5分鐘
        Track #1: Oligonucleotides
        分會1：寡核苷酸
        Chairperson’s Remarks: Track 1
        主席致辭：分會1
          10:55am - 11:00am5分鐘
          Track #2: Peptides
          分會2：胜肽
          Chairperson’s Remarks: Track 2
          主席致辭：分會2
            11:00am - 11:30am30分鐘
            Track #1: Oligonucleotides
            分會1：寡核苷酸
            Probing Chemical Space to Improve siRNA Therapeutic Profile
            研究化學空間以改善 siRNA 的治療效果
            • Mehran Nikan, PhD - Research Fellow, Ionis Pharmaceuticals
            11:00am - 11:30am30分鐘
            Track #2: Peptides
            分會2：胜肽
            Revolutionizing Healthcare: Pioneering Peptide Innovations by AI Computational Design
            改變醫療保健：透過人工智慧運算設計引領胜肽創新
            • Kerry Blanchard, MD, PhD - CEO, Chairman and Founder, Perpetual Medicines
            11:30am - 12:00pm30分鐘
            Track #1: Oligonucleotides
            分會1：寡核苷酸
            Development of Targeted RNA Therapeutics: Preclinical, Clinical Progress and Lessons Learned
            靶向 RNA 療法的開發：臨床前和臨床試驗的進展和經驗教訓
            • Hanhua Huang, PhD - Vice President, Biology, Avidity Biosciences
            11:30am - 12:00pm30分鐘
            Track #2: Peptides
            分會2：胜肽
            Identification of Disulfide Constrained Peptide Based Binders against Membrane Bound E3 Ubiquitin Ligases
            鑒定細胞膜結合的 E3 泛素連接酶的二硫鍵限制性肽結合物
            • Xinxin Gao, PhD - Principal Scientific Manager, Peptide Therapeutics, Genentech
            12:00pm - 12:30pm30分鐘
            Track #1: Oligonucleotides
            分會1：寡核苷酸
            Advancing Oligonucleotide and Gene Editing: Enhanced Capabilities Through Synergy
            寡核苷酸和基因編輯的進步：通過協同作用增強功能
            • Blake Unterreiner - Associate VP, Business Development & Customer Relations, NASD, Agilent Technologies
            12:00pm - 12:30pm30分鐘
            Track #2: Peptides
            分會2：胜肽
            First De-novo Designed Cyclic Peptides for SORT1 and CNS Delivery
            首個用於 SORT1 和 CNS 遞送的從頭設計的環肽
            • Lucas Siow - CEO and Co-Founder, ProteinQure
            12:30pm - 1:40pm70分鐘
            Networking Luncheon with Poster and Exhibit Viewing
            休憩時間・午餐會，觀賞海報和展覽
              1:40pm - 1:45pm5分鐘
              Track #1: Oligonucleotides
              分會1：寡核苷酸
              Chairperson’s Remarks: Track 1
              主席致辭：分會1
                1:40pm - 1:45pm5分鐘
                Track #2: Peptides
                分會2：胜肽
                Chairperson’s Remarks: Track 2
                主席致辭：分會2
                  1:45pm - 2:15pm30分鐘
                  Track #1: Oligonucleotides
                  分會1：寡核苷酸
                  Design and Selection of High-Affinity XenoAptamers for Diagnostic and Therapeutic Applications
                  用於診斷和治療的高親和力異適配體的設計與選擇
                  • Michiko Kimoto, PhD - Chief Operating Officer, R&D Director, Xenolis Pte. Ltd.
                  1:45pm - 2:15pm30分鐘
                  Track #2: Peptides
                  分會2：胜肽
                  Program Update on JNJ-2113, The First and Only Investigational Targeted Oral Peptide for Psoriasis
                  JNJ-2113計畫最新進展：第一個也是唯一一個進入臨床試驗的銀屑病標靶口服胜肽
                  • Steven Fakharzadeh, MD, PhD - Global Medical Affairs Leader Immunodermatology, Janssen
                  2:15pm - 2:45pm30分鐘
                  Track #1: Oligonucleotides
                  分會1：寡核苷酸
                  Nitto Bispecific siRNA Targeting YAP1/WWTR1 As A Novel Therapeutic Agent for Liver Fibrosis
                  作為肝纖維化新型治療劑的日東電工的 YAP1/WWTR1 標靶雙特異性 siRNA
                  • Masayuki Sugimoto, PhD - Manager, Nitto Denko Corporation
                  2:15pm - 2:45pm30分鐘
                  Track #2: Peptides
                  分會2：胜肽
                  Oral Peptide Therapeutics for Gut Disorders
                  治療腸道疾病的口服肽
                  • Markus Muttenthaler, PhD - Associate Professor, Neuropeptide Research, The University of Queensland and University of Vienna
                  2:45pm - 3:15pm30分鐘
                  Track #1: Oligonucleotides
                  分會1：寡核苷酸
                  Recent Progress of Luxna’s Antisense Oligonucleotide Therapeutics Platform and Application to Neurological Diseases
                  Luxna的反義寡核苷酸治療平台及其在神經系統疾病中的應用：最新研究成果
                  • Hideaki Sato - President and CEO, Luxna Biotech
                  2:45pm - 3:15pm30分鐘
                  Track #2: Peptides
                  分會2：胜肽
                  Biodegradable Silica Composite Technology Enabling Long-Acting Controlled Release of GLP-1RAs
                  利用可生物降解二氧化矽複合技術實現GLP-1RA長效控釋
                  • Lasse Leino, PhD - Chief Executive Officer, Adjunct Professor, DelSiTech Ltd.
                  3:15pm - 3:45pm30分鐘
                  Networking Refreshment Break with Poster and Exhibit Viewing
                  互動交流休息時間，觀賞海報和展覽
                    3:45pm - 4:15pm30分鐘
                    Track #1: Oligonucleotides
                    分會1：寡核苷酸
                    Reviving ANGPTL4 As a Drug Target with a GalNAc ASO Approach - A Case Study
                    使用 GalNAc ASO 方法恢復 ANGPTL4 作為藥物標靶：案例研究
                    • Stefan Nilsson, Ph.D. - CEO, Lipigon Pharmaceuticals AB
                    3:45pm - 4:15pm30分鐘
                    Track #2: Peptides
                    分會2：胜肽
                    Discovery of Macrocyclic Peptide Inhibitors of SIRT7 and HDAC11
                    SIRT7 和 HDAC11 大環肽抑製劑的發現
                    • Christian Adam Olsen, PhD - Professor, Drug Design and Pharmacology, University of Copenhagen
                    4:15pm - 4:45pm30分鐘
                    Track #1: Oligonucleotides
                    分會1：寡核苷酸
                    Recent Progress in the Treatment of Myotonic Dystrophy Type 1 (DM1), The Most Common Adult-onset Muscular Dystrophy
                    1 型強直性肌肉營養不良症 (DM1)最常見的成人發病性肌肉營養不良症治療的最新進展
                    • Frederic Legros, PhD - CEO, ARTHEx Biotech
                    4:15pm - 4:45pm30分鐘
                    Track #2: Peptides
                    分會2：胜肽
                    Preclinical Studies of Macrocyclic Peptides, Targeted Radiopharmaceutical Agents for PDL-1, Developed with 48Hour Discovery Pipeline
                    透過48 小時藥物發現管道開發的大環肽、PDL-1 靶向放射性藥物的臨床前研究
                    • Ratmir Derda, PhD - Founder and CSO, 48 Hour Discovery, University of Alberta
                    4:45pm - 5:15pm30分鐘
                    Track #1: Oligonucleotides
                    分會1：寡核苷酸
                    The Use of Oligonucleotides in the Treatment of Neurodegenerative Disorders
                    寡核苷酸在神經退化性疾病治療的應用
                    • Michael Gold, MD - Chief R&D Officer, Compass Pathways
                    4:45pm - 5:15pm30分鐘
                    Track #2: Peptides
                    分會2：胜肽
                    Combining Advanced Peptide Screening Methods to Identify Macrocyclic Peptide Candidates for Radiotherapy Development
                    結合先進的胜肽篩選方法來鑑定用於放射治療開發的大環肽候選物
                    • Weiliang Xu, PhD - Associate Director of Business Development, PepLib
                    5:15pm - 5:20pm5分鐘
                    Close of Conference
                    會議結束
                      主會議 第2天

                      * 活動內容有可能不事先告知作更動及調整。